arrow
M

Mona Parmar

The Institute of Cancer Research
H指数:13
被引数:689

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial

IAP拮抗剂托利那潘特(ASTX660)联合帕博利珠单抗治疗晚期实体瘤:一项I期临床试验

2026-09-300
OA
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

德法替尼联合阿瓦替尼治疗实体瘤患者: 1期框架试验

2025-06-270
OAAI
Proof-of-concept and preliminary efficacy of triple IAP blockade to maximize immunogenic cell death and induce efficient adaptive immune response: First report on the ASTEROID phase 1 trial
2024-04-050
PRE
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

靶向髓系趋化逆转前列腺癌治疗耐药

Nature
IF48.5
2023-10-160
OAAI
Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787)
2023-04-142
PRE
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

guadecitabine (SGI-110) 联合pembrolizumab治疗实体瘤患者的1期剂量递增研究

2022-06-1826
OAAI
Triplet Therapy with Palbociclib, Taselisib, and fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
2021-01-0645
OAAI
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers

PARP抑制剂Olaparib和AKT抑制剂Capivasertib在BRCA1/2和Non-BRCA1/2突变型癌症患者中的I期试验

2020-10-0192
OAAI
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
2018-09-0125
OAAI
Phase I trial combining the PARP inhibitor olaparib (01a) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations
2016-07-1510
PRE
Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
2015-08-016
PRE